The aim of this study was to retrospectively analyze the clinical and pathologic data of a series of patients presenting to our unit with uterine malignant mixed Müllerian tumors (MMMT) to attempt to identify prognostic factors and relate them to survival. Thirty-seven patients diagnosed with MMMT of the uterus from 1988 through 2000 were identified from the gynecological tumor registry. Data was abstracted and analyzed. The effect of a variety of clinical, histopathologic, and surgical variables on recurrence and survival were analyzed by univariate and multivariate analyses. Patients tended to be postmenopausal, overweight, hypertensive, and presented with abnormal bleeding. Preoperatively 28 (76%) were thought to have clinical stage I-II disease. Nine (32%) were upstaged based on surgical data. Five (56%) of these patients were found to have gross extrauterine disease and four (44%) were found subsequently to have microscopic extrauterine disease. Twenty (54%) patients underwent lymph node dissection and positive nodes were found in seven (35%) patients. Nine patients underwent omentectomy and disease was found in three (33%). Peritoneal washings were positive in three of 16 patients (19%). At the completion of primary surgery, 27 (75%) patients had no residual disease. Twelve (44%) of these patients had recurrence of disease. Median disease-free interval prior to first recurrence was 15 months. Median overall survival was 30 months. Log-rank analysis performed on multiple variables, including stage, age, residual disease, and depth of myometrial invasion showed a statistically significant association with overall survival probability. Only stage remained a significant independent variable predictive of overall survival (P = 0.034). We found that stage was an independent prognostic factor for overall survival in patients with uterine MMMT. Age, depth of myometrial invasion, and residual tumor were significant prognostic factors on univariate analysis. These factors may be a guide in order to select a group of high risk patients that may benefit from adjuvant therapy.

Asian Pac J Cancer Prev, 15 (1), [423][424][425][426] IntroductionCervical cancer is the second most common malignancy in women worldwide after breast cancer (Ferlay et al.). In Thailand, its incidence was 17.7/100,000 of Thai female population during (Khunhaprema et al., 2012. Cervical cancer incidences and deaths have decreased since the implementation of widespread cervical cancer screening with cervical cytology and/or human papilloma virus (HPV) (Saslow et al., 2012). The knowledge of HPV has been advanced. However, the cervical cytology is still the mainstay of cervical cancer screening. Colposcopy is the next investigation step for abnormal cervical screening patients after the followings; a) two consecutive unsatisfactory cytology results; b) most cases of positive HPV testing; c) repeated atypical squamous cell of undetermined significance (ASC-US) cytology; d) low grade squamous intraepithelial lesion (LSIL) cytology; e) atypical squamous cell, cannot exclude high grade squamous intraepithelial lesion (ASC-H) cytology; f) high grade squamous intraepithelial lesion (HSIL) cytology; g) some types of glandular abnormality (Massad et al., 2013

Malignant mixed mullerian tumour of the ovary is a rare and aggressive gynaecological tumour. The current study indicates that patient age was a significant prognostic factor for survival and surgical cytoreduction combined with platinum-based chemotherapy is the most effective management regimen identified to date to treat MMMT of the ovary.

The prevalence of patients with CIN1 or less from LEEP specimens who previously had colposcopic biopsies proven CIN2 or 3 was 16.3%. CIN2 from biopsy was the statistically significant risk factor of CIN1 or less in LEEP specimens.